http://orcid.org/0000-0001-5420-279X
Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
B. B. Hansen, S. Nuhoho, S. N. Ali, T. Dang-Tan, W. J. Valentine, S. J. P. Malkin & B. Hunt. (2020) Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Journal of Medical Economics 23:6, pages 650-658.
Read now
Read now
LK Billings, M Mocarski, A Basse, B Hunt, WJ Valentine & E Jodar. (2019) Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. ClinicoEconomics and Outcomes Research 11, pages 271-282.
Read now
Read now
Dhvani Shah, Nancy A Risebrough, Johnna Perdrizet, Neeraj N Iyer, Cory Gamble & Tam Dang-Tan. (2018) Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. ClinicoEconomics and Outcomes Research 10, pages 791-803.
Read now
Read now
Articles from other publishers (5)
Reema R. Mody, Kellie L. Meyer, Jennifer M. Ward & Ken B. O’Day. (2023) Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 14:12, pages 2045-2055.
Crossref
Crossref
Barnaby Hunt, Brian B. Hansen, Åsa Ericsson, Klaus Kallenbach, Sarah N. Ali, Tam Dang-Tan, Samuel J. P. Malkin & William J. Valentine. (2019) Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in Therapy 36:12, pages 3483-3493.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
C. K. Svensson, J. R. Larsen, L. Vedtofte, M. S. L. Jakobsen, H. R. Jespersen, M. I. Jakobsen, K. Koyuncu, O. Schjerning, J. Nielsen, C. T. Ekstrøm, C. U. Correll, T. Vilsbøll & A. Fink-Jensen. (2019) One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatrica Scandinavica 139:1, pages 26-36.
Crossref
Crossref
Marc Evans, Sayeed Achha & Cheryl Neslusan. (2017) Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Diabetes Therapy 8:5, pages 1175-1185.
Crossref
Crossref